Amphastar Pharmaceuticals Inc
AMPH
查看详细走势图
29.260USD
+0.630+2.20%
收盘 02/06, 16:00（美东）报价延迟15分钟
1.36B总市值
12.41市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.20%
5天
+10.46%
1月
+7.06%
6月
+35.34%
今年开始到现在
+9.26%
1年
-9.61%
查看详细走势图
TradingKey Amphastar Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Amphastar Pharmaceuticals Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名29/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价31.57。中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Amphastar Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Amphastar Pharmaceuticals Inc亮点
亮点风险
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
业绩高增长
公司营业收入稳步增长，连续3年增长46.69%
利润高增长
公司净利润处于行业前列，最新年度总收入731.97M美元
估值合理
公司最新PE估值12.41，处于3年历史合理位
机构加仓
最新机构持股33.97M股，环比增加0.05%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值542.00
分析师目标
根据
6
位分析师
买入
评级
31.571
目标均价
+10.35%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Amphastar Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Amphastar Pharmaceuticals Inc简介
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
公司代码AMPH
公司Amphastar Pharmaceuticals Inc
CEOZhang (Yongfeng Yongfeng)
网址https://amphastar.com/
相关品种
